Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, Tao X, Höhl R, Holzgrabe U, Kees F, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jun 18;11(6). pii: E286. doi: 10.3390/pharmaceutics11060286.

2.

Künstliche Intelligenz geht ans Telefon.

Höhl R.

MMW Fortschr Med. 2019 May;161(9):34. doi: 10.1007/s15006-019-0501-0. German. No abstract available.

PMID:
31079381
3.

Cancer and the Dopamine D2 Receptor: A Pharmacological Perspective.

Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ.

J Pharmacol Exp Ther. 2019 Jul;370(1):111-126. doi: 10.1124/jpet.119.256818. Epub 2019 Apr 18.

PMID:
31000578
4.

The Effect of Single-Dose Massage Session on Autonomic Activity, Mood, and Affective Responses in Major Depressive Disorder.

Hohl R, Deslandes AC, Mármora CHC.

J Holist Nurs. 2019 Feb 27:898010119832493. doi: 10.1177/0898010119832493. [Epub ahead of print]

PMID:
30810079
5.

Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity.

Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD.

Oncoimmunology. 2018 Nov 11;8(2):e1539614. doi: 10.1080/2162402X.2018.1539614. eCollection 2019.

PMID:
30713799
6.

Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia.

Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Shike H, Bayerl MG, Sivik JM, Schell TD, Drabick JJ, Hohl RJ, Zheng H.

Cancer Res. 2019 Apr 1;79(7):1635-1645. doi: 10.1158/0008-5472.CAN-18-3107. Epub 2019 Feb 1.

PMID:
30709927
7.

Brain cholesterol metabolism and Parkinson's disease.

Huang X, Sterling NW, Du G, Sun D, Stetter C, Kong L, Zhu Y, Neighbors J, Lewis MM, Chen H, Hohl RJ, Mailman RB.

Mov Disord. 2019 Mar;34(3):386-395. doi: 10.1002/mds.27609. Epub 2019 Jan 25.

PMID:
30681742
8.

Schweinfurthins: Lipid Modulators with Promising Anticancer Activity.

Koubek EJ, Weissenrieder JS, Neighbors JD, Hohl RJ.

Lipids. 2018 Aug;53(8):767-784. doi: 10.1002/lipd.12088. Epub 2018 Oct 17. Review.

PMID:
30334267
9.

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H.

Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.

10.

Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.

Weissenrieder JS, Reilly JE, Neighbors JD, Hohl RJ.

Prostate. 2019 Jan;79(1):21-30. doi: 10.1002/pros.23707. Epub 2018 Aug 14.

PMID:
30106164
11.

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H.

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4. No abstract available.

12.

Und wann killen Sie Ihr Praxis-Fax?

Höhl R.

MMW Fortschr Med. 2017 Oct;159(17):36. doi: 10.1007/s15006-017-0117-3. German. No abstract available.

PMID:
28994077
13.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Kauffman EPS, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Aug 14;32(2):268. doi: 10.1016/j.ccell.2017.07.008. No abstract available.

14.

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.

15.

Cancer Therapy: Shooting for the Moon.

Lee J, Blumenthal GM, Hohl RJ, Huang SM.

Clin Pharmacol Ther. 2017 May;101(5):552-558. doi: 10.1002/cpt.655. No abstract available.

16.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.

17.

Application of ICH Q9 Quality Risk Management Tools for Advanced Development of Hot Melt Coated Multiparticulate Systems.

Stocker E, Becker K, Hate S, Hohl R, Schiemenz W, Sacher S, Zimmer A, Salar-Behzadi S.

J Pharm Sci. 2017 Jan;106(1):278-290. doi: 10.1016/j.xphs.2016.09.025. Epub 2016 Nov 11.

PMID:
27842971
18.

[Pharmacokinetics and pharmacodynamics of antibiotics in intensive care].

Sörgel F, Höhl R, Glaser R, Stelzer C, Munz M, Vormittag M, Kinzig M, Bulitta J, Landersdorfer C, Junger A, Christ M, Wilhelm M, Holzgrabe U.

Med Klin Intensivmed Notfmed. 2017 Feb;112(1):11-23. doi: 10.1007/s00063-016-0185-5. Epub 2016 Oct 24. Review. German.

PMID:
27778050
19.

Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis.

Reilly JE, Neighbors JD, Hohl RJ.

Cancer Biol Ther. 2017 Nov 2;18(11):872-882. doi: 10.1080/15384047.2016.1219817. Epub 2016 Sep 13.

20.

GBM-associated mutations and altered protein expression are more common in young patients.

Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB.

Oncotarget. 2016 Oct 25;7(43):69466-69478. doi: 10.18632/oncotarget.11617.

21.

Anticoagulants: Major Advances Without Clear Consensus.

Hohl RJ.

Clin Pharmacol Ther. 2016 Aug;100(2):116-8. doi: 10.1002/cpt.399.

PMID:
27393187
22.

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.

Raje NS, Faber EA Jr, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC.

Clin Cancer Res. 2016 Dec 1;22(23):5688-5695. Epub 2016 Jun 10.

23.

[Now the doctors themselves distribute the fee].

Höhl R.

MMW Fortschr Med. 2016 May 25;158(10):36-7. doi: 10.1007/s15006-016-8264-3. German. No abstract available.

PMID:
27221420
24.

Monitoring of a Hot Melt Coating Process via a Novel Multipoint Near-Infrared Spectrometer.

Hohl R, Scheibelhofer O, Stocker E, Behzadi SS, Haack D, Koch K, Kerschhaggl P, Lochmann D, Sacher S, Zimmer A.

AAPS PharmSciTech. 2017 Jan 1;18(1):182-193. doi: 10.1208/s12249-016-0504-4. Epub 2016 Mar 2.

PMID:
26935562
25.

3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines.

Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ.

Lipids. 2015 Dec;50(12):1195-207. doi: 10.1007/s11745-015-4083-z. Epub 2015 Oct 22.

26.

Dynamic cross-flow filtration: enhanced continuous small-scale solid-liquid separation.

Gursch J, Hohl R, Dujmovic D, Brozio J, Krumme M, Rasenack N, Khinast J.

Drug Dev Ind Pharm. 2016;42(6):977-84. doi: 10.3109/03639045.2015.1100200. Epub 2015 Oct 22.

PMID:
26489453
27.

Continuous Processing of Active Pharmaceutical Ingredients Suspensions via Dynamic Cross-Flow Filtration.

Gursch J, Hohl R, Toschkoff G, Dujmovic D, Brozio J, Krumme M, Rasenack N, Khinast J.

J Pharm Sci. 2015 Oct;104(10):3481-9. doi: 10.1002/jps.24562. Epub 2015 Jul 3.

PMID:
26147786
28.

Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.

Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ.

Clin Exp Metastasis. 2015 Aug;32(6):555-66. doi: 10.1007/s10585-015-9727-0. Epub 2015 Jun 13.

29.

Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil.

Sheehy RM, Kuder CH, Bachman Z, Hohl RJ.

Cancer Biol Ther. 2015;16(8):1259-68. doi: 10.1080/15384047.2015.1056420. Epub 2015 Jun 5.

30.

[All outside data are immediately available].

Höhl R.

MMW Fortschr Med. 2015 Apr 30;157(8):8-9. doi: 10.1007/s15006-015-2998-1. German. No abstract available.

PMID:
26012653
31.

Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis.

Osborn-Heaford HL, Murthy S, Gu L, Larson-Casey JL, Ryan AJ, Shi L, Glogauer M, Neighbors JD, Hohl R, Carter AB.

Free Radic Biol Med. 2015 Sep;86:47-56. doi: 10.1016/j.freeradbiomed.2015.04.031. Epub 2015 May 7.

32.

In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.

Reilly JE, Zhou X, Tong H, Kuder CH, Wiemer DF, Hohl RJ.

Biochem Pharmacol. 2015 Jul 15;96(2):83-92. doi: 10.1016/j.bcp.2015.04.009. Epub 2015 May 4.

33.

Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.

Ferguson NN, Thomas CP, Hohl RJ, Syrbu SI, Stone MS, Wanat KA.

Am J Dermatopathol. 2015 Oct;37(10):790-4. doi: 10.1097/DAD.0000000000000272. Review.

PMID:
25747810
34.

Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.

Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ.

Invest New Drugs. 2015 Jun;33(3):594-602. doi: 10.1007/s10637-015-0220-z. Epub 2015 Feb 21.

PMID:
25698442
35.

Oncology trial design: More accurately and efficiently advancing the field.

Hohl RJ.

Clin Pharmacol Ther. 2015 May;97(5):430-2. doi: 10.1002/cpt.94. No abstract available.

PMID:
25684240
36.

[Healthy Kinzig Valley. The patient determines the therapy goal].

Höhl R.

MMW Fortschr Med. 2014 Nov 6;156(19):10-1. German. No abstract available.

PMID:
25509996
37.

Drug development (and academic medicine): charting the course forward.

Hohl RJ.

Clin Pharmacol Ther. 2014 Nov;96(5):519-22. doi: 10.1038/clpt.2014.171.

PMID:
25336261
38.

Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase.

Zhou X, Reilly JE, Loerch KA, Hohl RJ, Wiemer DF.

Beilstein J Org Chem. 2014 Jul 18;10:1645-50. doi: 10.3762/bjoc.10.171. eCollection 2014.

39.

Continuous API-crystal coating via coacervation in a tubular reactor.

Besenhard MO, Thurnberger A, Hohl R, Faulhammer E, Rattenberger J, Khinast JG.

Int J Pharm. 2014 Nov 20;475(1-2):198-207. doi: 10.1016/j.ijpharm.2014.08.009. Epub 2014 Aug 7.

PMID:
25109256
40.

[A new income advantage for physicians].

Höhl R.

MMW Fortschr Med. 2013 Jun 13;155(11):12. German. No abstract available.

PMID:
23901562
41.

Personalized medicine: through the looking glass of functional imaging.

Hohl RJ.

Clin Cancer Res. 2013 Aug 1;19(15):4024-6. doi: 10.1158/1078-0432.CCR-13-1129. Epub 2013 Jun 19.

42.

[Virtual accounting documents. Digitally into a tax pitfall?].

Höhl R.

MMW Fortschr Med. 2013 Mar 7;155(4):12. German. No abstract available.

PMID:
23614182
43.

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.

Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF.

Leukemia. 2013 Apr;27(4):977-80. doi: 10.1038/leu.2012.264. Epub 2012 Sep 11. No abstract available.

PMID:
23032694
44.

Quantitative determination of isopentenyl diphosphate in cultured mammalian cells.

Tong H, Kuder CH, Wasko BM, Hohl RJ.

Anal Biochem. 2013 Feb 1;433(1):36-42. doi: 10.1016/j.ab.2012.09.001. Epub 2012 Sep 19.

PMID:
23000003
45.

High oxidative capacity and type IIx fibre content in springbok and fallow deer skeletal muscle suggest fast sprinters with a resistance to fatigue.

Curry JW, Hohl R, Noakes TD, Kohn TA.

J Exp Biol. 2012 Nov 15;215(Pt 22):3997-4005. doi: 10.1242/jeb.073684. Epub 2012 Aug 16.

46.

Interaction between overtraining and the interindividual variability may (not) trigger muscle oxidative stress and cardiomyocyte apoptosis in rats.

Ferraresso RL, de Oliveira R, Macedo DV, Nunes LA, Brenzikofer R, Damas D, Hohl R.

Oxid Med Cell Longev. 2012;2012:935483. doi: 10.1155/2012/935483. Epub 2012 Jul 15.

47.

Is there a future for prenyltransferase inhibitors in cancer therapy?

Holstein SA, Hohl RJ.

Curr Opin Pharmacol. 2012 Dec;12(6):704-9. doi: 10.1016/j.coph.2012.06.013. Epub 2012 Jul 18. Review.

PMID:
22817869
48.

Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification.

Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ.

Mol Pharmacol. 2012 Jul;82(1):9-16. doi: 10.1124/mol.111.077107. Epub 2012 Mar 29.

49.

Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma.

Malchenko S, Seftor EA, Nikolsky Y, Hasegawa SL, Kuo S, Stevens JW, Poyarkov S, Nikolskaya T, Kucaba T, Wang M, Abdulkawy H, Casavant T, Morcuende J, Buckwalter J, Hohl R, Deyoung B, Kernstine K, Bonaldo Mde F, Hendrix MJ, Soares MB, Soares VM.

Sarcoma. 2012;2012:820254. doi: 10.1155/2012/820254. Epub 2012 Feb 16.

50.

A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H.

Cancer Prev Res (Phila). 2012 Apr;5(4):621-30. doi: 10.1158/1940-6207.CAPR-11-0455. Epub 2012 Jan 31.

Supplemental Content

Support Center